XML 78 R68.htm IDEA: XBRL DOCUMENT v3.22.2

Segment Reporting - Sales from Products (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Segment Reporting Information [Line Items]
Sales	$ 14,593	$ 11,402	$ 30,494	$ 22,029
Revenue related to the sale of the marketing rights			146	56
U.S.
Segment Reporting Information [Line Items]
Sales	6,238	5,100	13,577	9,890
Int’l
Segment Reporting Information [Line Items]
Sales	8,355	6,301	16,917	12,139
Operating Segments
Segment Reporting Information [Line Items]
Sales	14,223	11,452	29,812	22,108
Operating Segments | U.S.
Segment Reporting Information [Line Items]
Sales	6,203	5,106	13,449	9,837
Operating Segments | Int’l
Segment Reporting Information [Line Items]
Sales	8,020	6,345	16,362	12,271
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Sales	370	(50)	682	(79)
Corporate, Non-Segment | U.S.
Segment Reporting Information [Line Items]
Sales	35	(6)	128	53
Corporate, Non-Segment | Int’l
Segment Reporting Information [Line Items]
Sales	335	(44)	555	(132)
Pharmaceutical | Operating Segments
Segment Reporting Information [Line Items]
Sales	12,756	9,980	26,863	19,218
Pharmaceutical | Operating Segments | U.S.
Segment Reporting Information [Line Items]
Sales	5,726	4,647	12,498	8,941
Pharmaceutical | Operating Segments | Int’l
Segment Reporting Information [Line Items]
Sales	7,030	5,333	14,364	10,277
Pharmaceutical | Operating Segments | Keytruda
Segment Reporting Information [Line Items]
Sales	5,252	4,176	10,061	8,076
Pharmaceutical | Operating Segments | Keytruda | U.S.
Segment Reporting Information [Line Items]
Sales	3,197	2,347	5,976	4,528
Pharmaceutical | Operating Segments | Keytruda | Int’l
Segment Reporting Information [Line Items]
Sales	2,055	1,829	4,085	3,548
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza
Segment Reporting Information [Line Items]
Sales	275	248	541	475
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza | U.S.
Segment Reporting Information [Line Items]
Sales	143	124	283	242
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza | Int’l
Segment Reporting Information [Line Items]
Sales	132	124	257	233
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima
Segment Reporting Information [Line Items]
Sales	231	181	459	310
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima | U.S.
Segment Reporting Information [Line Items]
Sales	128	88	284	173
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima | Int’l
Segment Reporting Information [Line Items]
Sales	103	93	175	137
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl
Segment Reporting Information [Line Items]
Sales	33	0	86	0
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl | U.S.
Segment Reporting Information [Line Items]
Sales	28	0	55	0
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl | Int’l
Segment Reporting Information [Line Items]
Sales	5	0	30	0
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9
Segment Reporting Information [Line Items]
Sales	1,674	1,234	3,133	2,151
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 | U.S.
Segment Reporting Information [Line Items]
Sales	428	454	846	766
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 | Int’l
Segment Reporting Information [Line Items]
Sales	1,245	781	2,287	1,385
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax
Segment Reporting Information [Line Items]
Sales	578	516	1,047	965
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax | U.S.
Segment Reporting Information [Line Items]
Sales	434	386	805	718
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax | Int’l
Segment Reporting Information [Line Items]
Sales	143	130	243	246
Pharmaceutical | Operating Segments | RotaTeq
Segment Reporting Information [Line Items]
Sales	173	208	389	366
Pharmaceutical | Operating Segments | RotaTeq | U.S.
Segment Reporting Information [Line Items]
Sales	98	111	273	229
Pharmaceutical | Operating Segments | RotaTeq | Int’l
Segment Reporting Information [Line Items]
Sales	75	97	116	137
Pharmaceutical | Operating Segments | Pneumovax 23
Segment Reporting Information [Line Items]
Sales	153	152	325	323
Pharmaceutical | Operating Segments | Pneumovax 23 | U.S.
Segment Reporting Information [Line Items]
Sales	94	100	212	173
Pharmaceutical | Operating Segments | Pneumovax 23 | Int’l
Segment Reporting Information [Line Items]
Sales	59	52	114	150
Pharmaceutical | Operating Segments | Vaqta
Segment Reporting Information [Line Items]
Sales	35	56	71	90
Pharmaceutical | Operating Segments | Vaqta | U.S.
Segment Reporting Information [Line Items]
Sales	16	22	45	47
Pharmaceutical | Operating Segments | Vaqta | Int’l
Segment Reporting Information [Line Items]
Sales	19	34	25	43
Pharmaceutical | Operating Segments | Bridion
Segment Reporting Information [Line Items]
Sales	426	387	821	727
Pharmaceutical | Operating Segments | Bridion | U.S.
Segment Reporting Information [Line Items]
Sales	237	197	432	364
Pharmaceutical | Operating Segments | Bridion | Int’l
Segment Reporting Information [Line Items]
Sales	190	190	389	363
Pharmaceutical | Operating Segments | Prevymis
Segment Reporting Information [Line Items]
Sales	103	93	197	174
Pharmaceutical | Operating Segments | Prevymis | U.S.
Segment Reporting Information [Line Items]
Sales	47	37	87	72
Pharmaceutical | Operating Segments | Prevymis | Int’l
Segment Reporting Information [Line Items]
Sales	56	56	110	103
Pharmaceutical | Operating Segments | Primaxin
Segment Reporting Information [Line Items]
Sales	64	60	122	125
Pharmaceutical | Operating Segments | Primaxin | U.S.
Segment Reporting Information [Line Items]
Sales	0	0	1	0
Pharmaceutical | Operating Segments | Primaxin | Int’l
Segment Reporting Information [Line Items]
Sales	64	60	122	125
Pharmaceutical | Operating Segments | Dificid
Segment Reporting Information [Line Items]
Sales	66	34	119	61
Pharmaceutical | Operating Segments | Dificid | U.S.
Segment Reporting Information [Line Items]
Sales	63	32	113	56
Pharmaceutical | Operating Segments | Dificid | Int’l
Segment Reporting Information [Line Items]
Sales	3	2	6	4
Pharmaceutical | Operating Segments | Noxafil
Segment Reporting Information [Line Items]
Sales	60	66	118	133
Pharmaceutical | Operating Segments | Noxafil | U.S.
Segment Reporting Information [Line Items]
Sales	16	14	25	29
Pharmaceutical | Operating Segments | Noxafil | Int’l
Segment Reporting Information [Line Items]
Sales	45	52	92	104
Pharmaceutical | Operating Segments | Invanz
Segment Reporting Information [Line Items]
Sales	46	48	99	104
Pharmaceutical | Operating Segments | Invanz | U.S.
Segment Reporting Information [Line Items]
Sales	2	(4)	2	0
Pharmaceutical | Operating Segments | Invanz | Int’l
Segment Reporting Information [Line Items]
Sales	45	52	96	104
Pharmaceutical | Operating Segments | Cancidas
Segment Reporting Information [Line Items]
Sales	42	54	95	111
Pharmaceutical | Operating Segments | Cancidas | U.S.
Segment Reporting Information [Line Items]
Sales	2	1	4	3
Pharmaceutical | Operating Segments | Cancidas | Int’l
Segment Reporting Information [Line Items]
Sales	39	53	91	108
Pharmaceutical | Operating Segments | Zerbaxa
Segment Reporting Information [Line Items]
Sales	46	(1)	76	(9)
Pharmaceutical | Operating Segments | Zerbaxa | U.S.
Segment Reporting Information [Line Items]
Sales	22	(2)	40	(4)
Pharmaceutical | Operating Segments | Zerbaxa | Int’l
Segment Reporting Information [Line Items]
Sales	24	1	36	(5)
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo
Segment Reporting Information [Line Items]
Sales	98	74	170	149
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo | U.S.
Segment Reporting Information [Line Items]
Sales	88	81	159	149
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo | Int’l
Segment Reporting Information [Line Items]
Sales	10	(7)	11	0
Pharmaceutical | Operating Segments | Adempas
Segment Reporting Information [Line Items]
Sales	63	74	124	129
Pharmaceutical | Operating Segments | Adempas | U.S.
Segment Reporting Information [Line Items]
Sales	0	0	0	0
Pharmaceutical | Operating Segments | Adempas | Int’l
Segment Reporting Information [Line Items]
Sales	63	74	124	129
Pharmaceutical | Operating Segments | Lagevrio
Segment Reporting Information [Line Items]
Sales	1,177	0	4,424	0
Pharmaceutical | Operating Segments | Lagevrio | U.S.
Segment Reporting Information [Line Items]
Sales	0	0	1,523	0
Pharmaceutical | Operating Segments | Lagevrio | Int’l
Segment Reporting Information [Line Items]
Sales	1,177	0	2,901	0
Pharmaceutical | Operating Segments | Isentress/Isentress HD
Segment Reporting Information [Line Items]
Sales	147	192	305	401
Pharmaceutical | Operating Segments | Isentress/Isentress HD | U.S.
Segment Reporting Information [Line Items]
Sales	67	74	128	145
Pharmaceutical | Operating Segments | Isentress/Isentress HD | Int’l
Segment Reporting Information [Line Items]
Sales	80	118	177	256
Pharmaceutical | Operating Segments | Belsomra
Segment Reporting Information [Line Items]
Sales	69	78	137	157
Pharmaceutical | Operating Segments | Belsomra | U.S.
Segment Reporting Information [Line Items]
Sales	19	14	39	32
Pharmaceutical | Operating Segments | Belsomra | Int’l
Segment Reporting Information [Line Items]
Sales	50	63	98	125
Pharmaceutical | Operating Segments | Simponi
Segment Reporting Information [Line Items]
Sales	181	202	366	416
Pharmaceutical | Operating Segments | Simponi | U.S.
Segment Reporting Information [Line Items]
Sales	0	0	0	0
Pharmaceutical | Operating Segments | Simponi | Int’l
Segment Reporting Information [Line Items]
Sales	181	202	366	416
Pharmaceutical | Operating Segments | Remicade
Segment Reporting Information [Line Items]
Sales	53	75	114	160
Pharmaceutical | Operating Segments | Remicade | U.S.
Segment Reporting Information [Line Items]
Sales	0	0	0	0
Pharmaceutical | Operating Segments | Remicade | Int’l
Segment Reporting Information [Line Items]
Sales	53	75	114	160
Pharmaceutical | Operating Segments | Januvia
Segment Reporting Information [Line Items]
Sales	756	784	1,535	1,593
Pharmaceutical | Operating Segments | Januvia | U.S.
Segment Reporting Information [Line Items]
Sales	301	284	626	632
Pharmaceutical | Operating Segments | Januvia | Int’l
Segment Reporting Information [Line Items]
Sales	455	500	909	961
Pharmaceutical | Operating Segments | Janumet
Segment Reporting Information [Line Items]
Sales	476	477	931	962
Pharmaceutical | Operating Segments | Janumet | U.S.
Segment Reporting Information [Line Items]
Sales	105	74	168	158
Pharmaceutical | Operating Segments | Janumet | Int’l
Segment Reporting Information [Line Items]
Sales	371	403	762	805
Pharmaceutical | Operating Segments | Other pharmaceutical
Segment Reporting Information [Line Items]
Sales	479	512	998	1,069
Pharmaceutical | Operating Segments | Other pharmaceutical | U.S.
Segment Reporting Information [Line Items]
Sales	191	213	372	429
Pharmaceutical | Operating Segments | Other pharmaceutical | Int’l
Segment Reporting Information [Line Items]
Sales	288	299	628	640
Animal Health | Operating Segments
Segment Reporting Information [Line Items]
Sales	1,467	1,472	2,949	2,890
Animal Health | Operating Segments | U.S.
Segment Reporting Information [Line Items]
Sales	477	459	951	896
Animal Health | Operating Segments | Int’l
Segment Reporting Information [Line Items]
Sales	990	1,012	1,998	1,994
Animal Health | Operating Segments | Livestock
Segment Reporting Information [Line Items]
Sales	826	821	1,658	1,640
Animal Health | Operating Segments | Livestock | U.S.
Segment Reporting Information [Line Items]
Sales	164	161	335	318
Animal Health | Operating Segments | Livestock | Int’l
Segment Reporting Information [Line Items]
Sales	662	659	1,322	1,322
Animal Health | Operating Segments | Companion Animals
Segment Reporting Information [Line Items]
Sales	641	651	1,291	1,250
Animal Health | Operating Segments | Companion Animals | U.S.
Segment Reporting Information [Line Items]
Sales	313	298	616	578
Animal Health | Operating Segments | Companion Animals | Int’l
Segment Reporting Information [Line Items]
Sales	$ 328	$ 353	$ 676	$ 672

X

- Definition

The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585

+ Details

Name:	us-gaap_ProceedsFromSaleOfIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingInformationLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	srt_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=mrk_InternationalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_KeytrudaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_LenvimaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_AllianceRevenueReblozylMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_RotateqMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_Pneumovax23Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_VaqtaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_BridionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_PrevymisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_PrimaxinMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_DificidMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_NoxafilMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_InvanzMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_CancidasMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_ZerbaxaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_AllianceRevenueAdempasVerquvoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_AdempasMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_LagevrioMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_IsentressIsentressHDMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_BelsomraMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_SimponiMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_RemicadeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_JanuviaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_JanumetMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_LivestockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_CompanionAnimalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: